BeOne Medicines received US accelerated approval for sonrotoclax (Beqalzi), a next-generation BCL2 inhibitor targeting relapsed or refractory mantle cell lymphoma following BTK inhibitor therapy. The approval positions BeOne to compete in an area where AbbVie and Roche’s Venclexta is already established off-label in practice. BeOne previously secured regulatory clearance in China for the program, and it emphasized the opportunity to expand combinations, including potential pairing with zanubrutinib (Brukinsa), as the company develops further clinical evidence in hematologic cancers.